Merck & Co. Inc. was the latest pharmaceutical giant to limit drug price increases and the company even rolled back the costs for some of its brands – albeit brands with slowing growth, modest sales and generic competitors – as political pressure continues to mount around prescription medicine pricing in the US.
[Sidebar#SC123450]





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
